![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus
|
|
|
Reported by Jules Levin
CROI 2013 Atlanta March 3-6
(Study 652-2-202; NCT01338883)
Joseph Gathe1, Jerry Cade2, Edwin DeJesus3, Judith Feinberg4, Jay Lalezari5, Javier O. Morales Ramirez6, Anthony Scarsella7, Michael Saag8, Melanie Thompson9, Eric Lefebvre10
1Therapeutic Concepts, Houston, TX, US; 2Nevada AIDS Res Ed Society, Las Vegas, NV, US; 3Orlando Immunology Ctr, Orlando, FL, US; 4Univ Cincinnati, Cincinnati, OH, US; 5Quest Clin Res, San Francisco, CA, US; 6Clin Res P.R., Inc.,
San Juan, Puerto Rico; 7Pacific Oaks Med Grp, Beverly Hills, CA, US; 8Univ Alabama at Birmingham, Birmingham, AL, US; 9AIDS Res Consortium of Atlanta, Atlanta, GA, US; 10Tobira Therapeutics Inc., San Francisco, CA, US
![CROI1.gif](../images/030813/031813-1/CROI1.gif)
![CROI2.gif](../images/030813/031813-1/CROI2.gif)
![CROI3.gif](../images/030813/031813-1/CROI3.gif)
![CROI4.gif](../images/030813/031813-1/CROI4.gif)
![CROI5.gif](../images/030813/031813-1/CROI5.gif)
![CROI6.gif](../images/030813/031813-1/CROI6.gif)
![CROI7.gif](../images/030813/031813-1/CROI7.gif)
![CROI8.gif](../images/030813/031813-1/CROI8.gif)
![CROI9.gif](../images/030813/031813-1/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|